MyPeptideMatchOverview
Tesamorelin is an FDA-approved growth hormone-releasing hormone (GHRH) analog sold as Egrifta and Egrifta SV. It is approved for reduction of excess abdominal fat in HIV-associated lipodystrophy—a specific indication in a patient population that often experiences fat redistribution and metabolic changes. Tesamorelin stimulates the pituitary to release growth hormone, which in turn supports fat metabolism and body composition in this context. Evidence for the approved indication is strong. Use outside the approved indication (e.g., general anti-aging or weight loss) is off-label and should be discussed with a knowledgeable provider.
How It Works (Mechanism of Action)
Tesamorelin mimics GHRH, stimulating pituitary release of growth hormone. Increased GH supports lipolysis and can reduce visceral fat in the approved population. The mechanism is similar in concept to sermorelin but with a distinct approved use.
Primary Uses
HIV-Associated Lipodystrophy
Egrifta is approved specifically for reduction of excess abdominal fat in HIV-positive adults with lipodystrophy. It is used as part of a comprehensive care plan. Evidence for this indication is strong.
